Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.

被引：4
|
作者：
Ohtsu, Atsushi
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Sun, Linda
Wang, Zhen
Csiki, Ildiko
Koshiji, Minori
Van Cutsem, Eric
机构：
[1] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] MSD China, Beijing, Peoples R China
[7] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps183
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS183
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Yung-Jue Bang
    Yoon-Koo Kang
    Daniel V. Catenacci
    Kei Muro
    Charles S. Fuchs
    Ravit Geva
    Hiroki Hara
    Talia Golan
    Marcelo Garrido
    Shadia I. Jalal
    Christophe Borg
    Toshihiko Doi
    Harry H. Yoon
    Mary J. Savage
    Jiangdian Wang
    Rita P. Dalal
    Sukrut Shah
    Zev A. Wainberg
    Hyun Cheol Chung
    Gastric Cancer, 2019, 22 : 828 - 837
  • [42] A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
    Si, Lu
    Zhang, Xiaoshi
    Shu, Yongqian
    Pan, Hongming
    Wu, Di
    Liu, Jiwei
    Lou, Fang
    Mao, Lili
    Wang, Xuan
    Wen, Xizhi
    Gu, Yanhong
    Zhu, Lingjun
    Lan, Shijie
    Cai, Xin
    Diede, Scott J.
    Zhou, Yu
    Ge, Zjun
    Li, Jianfeng
    Wu, Haiyan
    Guo, Jun
    TRANSLATIONAL ONCOLOGY, 2019, 12 (06): : 828 - 835
  • [43] Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.
    Chau, Ian
    Bendell, Johanna C.
    Calvo, Emiliano
    -Davila, Rafael Santana
    Arkenau, Hendrik-Tobias
    Mi, Gu
    Jin, Jin
    Rege, Jessicca
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction
    Zhang, Fengli
    Yin, Yanfen
    Ni, Tiantian
    Zhang, Mei
    Zhou, Zhou
    Sun, Xin
    Kuang, Wanghao
    Li, Ping
    PHARMAZIE, 2020, 75 (08): : 389 - 394
  • [45] Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma
    Moy, Ryan H.
    Greally, Megan
    Chou, Joanne F.
    Li, Jia
    Desai, Avni M.
    Chalasani, Sree B.
    Won, Elizabeth
    Kelsen, David P.
    Ilson, David H.
    Janjigian, Yelena Y.
    Capanu, Marinela
    Ku, Geoffrey Y.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (02) : 255 - 265
  • [46] A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Kelly, Ronan Joseph
    Castillo, Dani Ran
    Yamaguchi, Kensei
    Kato, Ken
    Kudo, Toshihiro
    Wainberg, Zev A.
    Rha, Sun Young
    Lee, Jeeyun
    Ryu, Min-Hee
    Okano, Fumiyoshi
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma
    Ryan H. Moy
    Megan Greally
    Joanne F. Chou
    Jia Li
    Avni M. Desai
    Sree B. Chalasani
    Elizabeth Won
    David P. Kelsen
    David H. Ilson
    Yelena Y. Janjigian
    Marinela Capanu
    Geoffrey Y. Ku
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 255 - 265
  • [48] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [49] Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.
    Al-Batran, Salah-Eddin
    Shitara, Kohei
    Folprecht, Gunnar
    Moehler, Markus H.
    Goekkurt, Eray
    Ben-Aharon, Irit
    Lonardi, Sara
    Stein, Stacey
    Hubert, Ayala
    Chau, Ian
    Mishaeli, Moshe
    Villanueva, Luis
    Kavan, Petr
    Fang, Xiao
    Shih, Chie-Schin
    Bhagia, Pooja
    Wyrwicz, Lucjan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 247 - 247
  • [50] FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy - The phase II/III RAMIRIS study
    Al-Batran, S-E.
    Gotze, T. O.
    Dechow, T.
    Goekkurt, E.
    Algul, H.
    Decker, T.
    Becker, S. Hegewisch
    Hofheinz, R. D.
    Mohler, M.
    Stahl, M.
    Thuss-Patience, P. C.
    Herzer, S.
    Pauligk, C.
    Lorenzen, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S930 - S930
12345